{
    "nct_id": "NCT05878769",
    "official_title": "A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease",
    "inclusion_criteria": "* Completion of the 52-week treatment period in either parent GB43311 or GB44332\nHealthy volunteers allowed\nMust have minimum age of 40 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* Withdrawal of consent and/or premature discontinuation from parent study\n* Any permanent discontinuation of study drug in parent study\n* Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment\n* Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study\n* Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study\n* Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study",
    "miscellaneous_criteria": ""
}